GeneDx announced a strategic partnership with Komodo Health. The new partnership will increase access to GeneDx’s extensive de-identified rare disease data set, now available through Komodo Health’s MapEnhance offering, including data from more than 500,000 exomes, enabling biopharma companies to access genetic insights that can help inform drug pipelines and accelerate clinical trial enrollment.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WGS:
- GeneDx price target raised to $15 from $11 at BTIG
- GeneDx management to meet with BTIG
- GeneDx to Report First Quarter 2024 Financial Results on Monday, April 29, 2024
- GeneDx to present data on exome at ACMG meeting
- GeneDx to Present Data at the 2024 American College of Medical Genetics (ACMG) Annual Meeting Demonstrating Clinical Superiority of its Exome, Paving the Way for the Future of Genomics